Mukesh Loganathan

Mukesh Loganathan is a Venture Capitalist at Morningside Technology Advisory LLC since September 2022. Previously, Mukesh held the position of Cell Line Development Intern at Asimov from June to August 2022, developing processes to quantify cell line mAb titer levels. Co-founding UltraLoop Technologies in March 2020, Mukesh led the company in providing UVC sanitization solutions, achieving significant fundraising and successfully selling devices to UNC-Chapel Hill. Additionally, Mukesh served as a Research Assistant at the University of North Carolina at Chapel Hill School of Medicine in the Strahl Lab during the summer of 2021, focusing on histone post-translational modifications. Earlier experience includes an internship at the National Cancer Institute, where Mukesh worked on a CRISPR Cas 9 project utilizing human embryonic kidney cells. Mukesh holds a Bachelor's degree in Biology from the University of North Carolina at Chapel Hill and completed the VUS Program at Harvard University.